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Abstract 
Elevated levels of amyloid-β (Aβ) peptides, the main component of amyloid plaques in Alzheimer’s 
disease (AD), are the result of excessive β-and γ-cleavage of the amyloid precursor protein (APP) 
and/or impaired Aβ clearance. It has been suggested that high concentrations of luteinizing hormone 
(LH) in women contributes to increased Aβ generation after menopause, but the mechanism for this 
is incompletely understood. We investigated the effect of human chorionic gonadotropin (hCG), an 
LH receptor agonist, on APP β-cleavage in the SH-SY5Y neuroblastoma cell line. Treatment of 
these cells with hCG induced elevated β-cleavage in a dose-dependent manner: administration of 30 
mIU but not 10 mIU/ml of hCG significantly increased sAPPβ levels in the cell medium 1.7 fold as 
measured by Enzyme-linked Immunosorbent Assay (ELISA). These results support the notion that 
LH contributes to elevated Aβ levels at least in part by increasing β-cleavage of APP by BACE.  
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Introduction 
Hallmarks of Alzheimer’s disease (AD) include neurofibrillary tangles composed of intra-neuronal 
paired helical filaments of hyperphosphorylated tau protein and extracellular amyloid plaque 
deposits of aggregated amyloid-β (Aβ) peptides (Haass et al., 2012). Aβ peptides are derived from 
the trans-membrane amyloid precursor protein (APP) that is sequentially cleaved by proteolytic 
activities of β-secretase and γ-secretase (Haass et al., 2012). Activity of an additional secretase 
enzyme, α-secretase results in non-amyloidogenic processing of APP (Haass et al., 2012). APP is 
first cleaved in endosomes or at the plasma membrane by β-secretase or α-secretase enzymes 
releasing the large N-terminal APP ectodomains sAPPβ or sAPPα that are secreted from the cell. 
The membrane associated C-terminal fragment left after β-secretase activity is further processed by 
γ-secretase to generate Aβ. In AD, it is proposed that β-secretase activity followed by Aβ generation 
is favoured over α-secretase activity; hence, factors inducing β-secretase activity may contribute to 
the pathogenesis of AD (Haass et al., 2012). 
Luteinizing hormone (LH) is a sex hormone produced in the pituitary of both genders and regulates 
secretion of estrogens and androgens via the hypothalamus-pituitary-gonad (HPG) axis. Age-related 
changes in the HPG axis, particularly declined levels of estrogens in menopausal women, reflects 
sustained high levels of LH. It has been suggested that LH may contribute to the pathogenesis of 
AD (Barron et al., 2010; Short et al., 2001). In the brain, LH/hCG receptors are expressed in 
hippocampal and cortical structures affected by AD as well as other regions (Lei et al., 1993).  
Studies in vitro and in vivo in animal models have suggested roles of LH in the generation of AD-
like phenotypes. Studies in mice have shown that inhibition of LH release or suppression of LHR 
improved cognitive performance as measured in memory-based behavioral tests (Casadesus et al., 
2007). Other animal experiments demonstrated that LH or human chorionic gonadotropin (hCG), 
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that also acts on LHR, stimulated the production of APP (Porayette et al, 2007) and secreted Aβ 
peptide (Wahjoepramono et al., 2011). Studies in vitro using the M17 neuroblastoma cell line 
showed that treatment with LH increased Aβ production however the mechanism for this remains 
unclear (Bowen et al., 2004). Using a similar neuroblastoma cell model (SH-SY5Y), we sought to 
investigate specifically whether LH/hCG receptor activation triggers β-cleavage of APP. LH-
mediated increases in the activity of the β-secretase BACE may be a mechanism whereby LH could 
stimulate Aβ generation. 
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Materials and Methods 
Cell culture and differentiation 
SH-SY5Y neuroblastoma cells were maintained in high glucose DMEM supplemented with 10% 
FBS, penicillin, and streptomycin (Invitrogen). The cells were maintained at 37°C/5% CO2 and 
media was changed every 3 days. All-trans retinoic acid (ATRA) (Sigma-Aldrich) was diluted to1 
µM in DMEM with supplements and added to cells for 7 days to induce cell differentiation. Human 
chorionic gonadotropin (hCG) was added to cells in Neurobasal medium supplemented with 1% 
FBS, 2% B27, 1% glutamax, penicillin, and streptomycin (Invitrogen). The hCG was prepared by 
dissolving 1 ampulla of hCG (Organon Pharmaceuticals, USA) in 1 ml of autoclaved water. Each 
ampulla contains 5000 International Unit (IU) of hCG powder; hence, the stock concentration was 
5000 IU/mL. The stock hCG solution was serially diluted into the cell media to generate the 
required concentrations. 
 
RNA extraction and PCR  
Cells were plated into 6-well plates (Corning) at a density of 2.0 × 106cells per well. After 2 days, 
some cells were treated with ATRA for a further 7 days. Cells were washed with ice cold PBS and 
then lysed with Trizol reagent and centrifuged at 12,000 g for 15 minutes at 4°C to extract the 
cellular RNA which was sequentially precipitated by applying isopropyl alcohol. The RNA pellet 
was then washed twice with 75% ethanol and air-dried and dissolved in (Diethylpyrocarbonate) 
DEPC-treated water. The purity and concentration of RNA was measured using a NanoVue plus 
spectrophotometer. LHR primer was designed using the Primer-Blast program. The High Capacity 
RNA-to-cDNA Master Mix kit (Applied Biosystems) was employed to synthesize cDNA from the 
purified cellular mRNA. PCR was conducted employing a Platinum Taq Polymerase kit 
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(Invitrogen). The TaqMan®Gene Expression Master Mix kit(Applied Biosystems) was used to 
synthesize cDNA from cellular RNA and conduct real-time PCR. 
 
hCG treatment and detection of total APP and secreted ectodomains 
Cells were plated into 6-well plates at a density of 2.0 × 106 cells per well. The following day, 
DMEM medium was replaced with supplemented Neurobasal medium to which 0 or 10 or 30 
mIU/ml of human chorionic gonadotropin (hCG) was added. At the end of the treatment period (day 
8), the culture medium was collected and centrifuged at 13000 g for 15 minutes at 4°C. The 
supernatant was used to conduct ELISA and Western blot to compare the levels of sAPPβ and 
sAPPα, respectively. The cell pellets were lysed to extract cellular protein. RIPA Lysis buffer 
consisted of TRIS (50 mM, pH:7.4), NaCl (150 mM), Na Deoxycholate (10%), NP-40 (10%), SDS 
(0.1%), distilled water, and freshly added protease inhibitor cocktail (Roche). Protein 
concentrations in lysates were measured using the Micro BCA protein assay reagent kit (Pierce). An 
AlphaLisa kit (PerkinElmer) was used to measure the concentrations of sAPPβ in cell medium 
according to the manufacturer’s protocol. To probe total APP, 6% acrylamide gels were prepared. 
Pre-cast 10% acrylamide gels (Invitrogen) were employed to probe sAPPα, and LHR. Mouse anti-
APP antibody (Signet, 6E10) was applied at 1:1000 dilution to probe Western blots for APP and 
sAPPα in cell lysates and culture medium, respectively. To detect LHR protein, 0.2 µl/ml (1:5000) 
of goat polyclonal anti-LHR antibody (Novus Biologicals) was used. As a loading control to 
normalize the band densities, mouse anti-GAPDH antibody (Sigma) was applied at 1:2000 dilution. 
Image J (NIH) and excel softwares were employed to calculate normalized band densities which 
were afterwards analyzed with Prism software to determine statistical significance.  
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Statistical Analysis 
The Mann-Whitney test was employed to measure the effect of retinoic acid administration on 
production and maturation of APP and the expression of LH-receptor. Bonferroni’s Multiple 
Comparison test was used to study the effect of hCG administration on β-cleavage of APP.  
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Results 
Studies in vitro using the M17 neuroblastoma cell line showed that treatment with LH increased Aβ 
production (Bowen et al., 2004). This study inferred an increase in β-cleavage of APP based on 
elevated levels of intracellular C99, which is the membrane bound product left behind after 
cleavage of APP by BACE. C99 is further processed by γ-secretase to generate Aβ or it is degraded 
by the proteasome (Watanabe et al., 2012). We sought to investigate this pathway further by 
measuring β-cleavage in neuroblastoma SH-SY5Y cells treated with hCG as the LHR agonist. 
Direct measurement of β-cleavage was achieved by using ELISA to detect the ectodomain sAPPβ 
released in to the cell media. 
 
As we did not find any previous literature demonstrating that SH-SY5Y cells express LHR, we first 
conducted RT-PCR (Fig. 1A, left panel) and Western blot (Fig. 1A, right panel) to investigate LHR 
gene expression and protein synthesis in SH-SY5Y cells and the effect of cell differentiation on 
APP expression and maturation. For this purpose, SH-SY5Y cells were treated with 1 µM all trans-
retinoic acid (ATRA) for 7 days. At the end of this period, significant morphological changes 
including rounding of perikarya and the development of thin neurite-like processes were observed 
which indicated cellular differentiation (Figure 1B, images). The results of Western blots were 
analyzed and showed that 1 µM ATRA administration significantly increased total intracellular 
APP levels (p < 0.05; Figure 1B, lower panels). Furthermore, an increase in slower-running bands 
representing the mature glycosylated forms of APP indicated that SH-SY5Y cell differentiation 
correlated with the maturation of APP through the secretory pathway (Fig.1B, arrows). By contrast, 
LHR levels were sometimes reduced after ATRA treatment. As some differentiated cells appeared 
to express reduced levels of LHR, undifferentiated SH-SY5Y cells were used for the following 
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experiments. Cells were treated for 8 days with 0, 10 or 30 mIU/ml of hCG. The media was 
replaced every other day. On the last day, we compared the levels of total APP, sAPPα and sAPPβ 
in the 3 groups. Total APP levels were measured by Western blot of protein lysates (Fig. 1C, upper 
panel). Quantification of the band densities showed that administration of neither 10 nor 30 mIU/ml 
of hCG significantly altered total APP synthesis although a trend to increased APP was observed 
(Fig. 1D, top) (p >0.05). The sAPPα levels were measured by applying Western blot of the culture 
medium (Fig. 1C, lower panel). This demonstrated that hCG administration caused a trend of 
decline in sAPPα production (Figure 1D, bottom). Although this reduction was not statistically 
significant, it did exhibit a dose-dependent pattern - p values for 10 and 30 mIU/mL were 0.5887 
and 0.0586, respectively. Finally, we conducted ELISA to measure the concentration of sAPPβ in 
the same culture medium (Fig. 1E and Supplementary Information). The mean concentration of 
sAPPβ was 343 pg/mL in the absence of hCG administration. When cells were treated with 10 
mIU/mL or 30 mIU/mL of hCG, the mean sAPPβ concentration increased to 429 pg/ml or 591 
pg/ml, respectively corresponding to a 1.3 or 1.7 fold elevation in sAPPβ secretion. The 1.7 fold 
increase at 30 mIU/mL of hCG was statistically significant (p < 0.005; Bonferroni’s Multiple 
Comparison test) (Fig. 1E).   
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Discussion 
We have shown that 30 mIU/mL hCG can significantly increase β-cleavage of APP and secretion of 
sAPPβ from SH-SY5Y neuroblastoma cells. This result is consistent with a previous study that 
showed intracellular C99 (the intracellular C-terminal membrane bound APP fragment left behind 
after β-cleavage by BACE) levels are increased in neuroblastoma cells treated with LH (Bowen et 
al., 2004). The apparent elevated BACE activity may be due to different scenarios – increased  
trafficking of BACE and/or APP to subcellular domains where cleavage takes place, increased 
expression of BACE or increases in BACE activity via other mechanisms. It has been shown that 
BACE protein and mRNA levels are elevated in AD, and that BACE activity but not necessarily 
protein levels are elevated during ageing (Holsinger et al., 2006; Fukumoto et al., 2004). This 
suggests that an age-related increase in BACE trafficking and activity and/or BACE expression 
levels could contribute to predisposition to AD. Age-related changes in hormonal signalling through 
LH could be one triggering mechanism for elevated APP β-cleavage in neurons. This is a 
reasonable hypothesis because brain regions affected by altered APP metabolism, amyloid 
accumulation and tau pathology early in AD, such as the entorhinal cortex and hippocampus, have 
been shown to express LHR in adults (Lei et al., 1993). The localization of LHR in these brain 
regions suggests potential diverse functional roles for LH-mediated signalling that have so far not 
been investigated (Apaja et al., 2004). 
 
The known cellular functions of LHR activation involve steroid hormone production and associated 
cholesterol transport and metabolism. However, little is known about LHR signalling in the brain or 
more specifically in neurons. Cholesterol is known to modulate APP metabolism in lipid rafts 
(Hicks et al., 2012). Cholesterol- and sphingolipid-rich membrane microdomains are involved in 
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regulating trafficking and processing of APP and active BACE resides in lipid rafts (Hicks et al., 
2012). It is possible then that LHR activation could exert its effect on BACE activity by modulating 
cholesterol transport and metabolism and the extent of BACE and APP localization in lipid rafts. 
Addressing these questions and dissecting the intracellular signalling cascade involved would open 
a new area of future work. 
 
Some epidemiologic studies have suggested that AD is more prevalent among women at old age 
(Miech et al., 2002). This hypothesis is supported by some limited studies that have shown that LH 
levels are higher in AD patients than age-matched controls (Short et al., 2001). Aging is a major 
risk factor for AD and postmenopausal women in particular have elevated levels of LH (Miech et 
al., 2002). Although some studies have suggested that hormone replacement therapy (HRT) may 
have protective effects against AD, this remains controversial as the period of HRT administration 
could be critical, encompassing the onset of menopause and the subsequent following early first 
years (Zandi et al., 2002). Considering that LH levels are maximal during this critical period and 
HRT suppresses LH production, it is conceivable that any beneficial effects of estrogen 
administration on reducing AD risk could be mediated in-part through reducing the level of 
circulating LH. Furthermore, people with Down’s syndrome have a high prevalence of AD, develop 
the disease at younger ages than the general population and also have relatively high levels of LH 
starting at puberty indicating abnormalities in primary gonadal function that correlate with earlier-
onset AD (Schupf et al., 1998).  
I(n summary, the demonstrated dose-dependent increase in β-secretase activity upon treatment of 
SH-SY5Y cells with the LHR agonist hCG suggests that reported LH/LHR-mediated increases in 
Aβ levels are due to activation of β-secretase. Elevated sAPPβ and Aβ production in vivo may be 
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generated in-part through LH binding to LHR-expressing neurons in the regions of the brain 
affected by AD that are potentially exposed to increased levels of LH during ageing and 
menopause.   
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Figure Legend 
Figure 1 
(A) Indication that LHR mRNA and protein is expressed in SH-SY5Y cells. A 655 bp fragment was 
amplified using LHR-specific primers (left panel). A 59 kDa protein band was observed on Western 
Blot consistent with LHR protein expression (right panel; probed with 0.2 μl/mL, 1:5000 anti-LHR 
goat antibody). (B) ATRA administration induces cell differentiation and stimulates APP 
production and maturation in SH-SY5Y cells. Lanes 1-3 and 4-6 are triplicate lysates from 
untreated and ATRA treated cell cultures respectively. (C) Treatment of SH-SY5Y cells with hCG 
followed by Western blot for total intracellular APP levels (upper panel) and sAPPα in cell media 
(lower panel). Representative examples of results from duplicate cultures treated with 0, 10 or 30 
mIU/ml hCG are shown from one of 3 experiments. (D) Quantification of the Western blot band 
densities in (C) and two other experiments (n= 6 samples for each condition). Total APP measured 
in cell lysates showed a trend to increase after treatment with hCG, but this was not statistically 
significant (top bar graph). By contrast, sAPPα  measured in the cell medium showed a trend to 
decline after treatment with hCG but this was also not statistically significant (lower bar graph) 
(p>0.05).  Western blots of SH-SY5Y cell lysates and cell media for detection of APP and sAPPα, 
respectively were probed using the mouse monoclonal 6E10 anti-APP antibody at 1:1000 dilution. 
(E) The concentrations of sAPPβ in the same sets of cell medium were measured by ELISA 
(AlphaLisa kit, Perkin Elmer). A significant increase in sAPPβ was observed with 30 mIU/ml (p = 
0.0029) but not 10 mIU/ml (p >0.05) hCG, demonstrating a dose dependent effect. Statistical 
significance was considered for p values <0.05. 
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